Kyle Amber to Rituximab
This is a "connection" page, showing publications Kyle Amber has written about Rituximab.
Connection Strength
0.788
-
Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris. J Dtsch Dermatol Ges. 2022 04; 20(4):520-521.
Score: 0.196
-
Pemphigus subtype: a confounder in determining the association of oral involvement with post-rituximab relapses. Dermatol Ther. 2019 05; 32(3):e12918.
Score: 0.161
-
Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018 04; 78(4):806-808.
Score: 0.145
-
Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States. J Am Acad Dermatol. 2015 Aug; 73(2):337-8.
Score: 0.124
-
Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris. Exp Dermatol. 2013 Nov; 22(11):699-704.
Score: 0.110
-
Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. Br J Dermatol. 2023 03 30; 188(4):499-505.
Score: 0.053